SCHEMBL711671

SCHEMBL711671

Cc1csc(NS(=O)(=O)c2ccc(Nc3nc(Cc4ccc(Cl)cc4)cs3)cc2F)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 6/20 0.53
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
RAB9A P51151 3/20 0.48
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 2/20 0.48
GAA P10253 2/20 0.48
POLB P06746 2/20 0.42
SCN5A Q14524 2/20 0.42
SCD O00767 1/20 0.39
KDM1A O60341 2/20 0.39
MAOA P21397 2/20 0.39
CACNA1G O43497 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
SCN1A P35498 1/20 0.38
SCN8A Q9UQD0 1/20 0.38
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713549 0.88 SCN9A (0.52) SCN9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL713939 0.86 SCN9A (0.70) SCN9AMAPTSMN1; SMN2SCN5ASCN1A
SCHEMBL714024 0.78 SCN9A (0.57) SCN9AKMT2AMEN1SCN5ASCN1A
SCHEMBL13962917 0.78 SCN9A (0.45) SCN9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL712134 0.77 SCN9A (0.62) SCN9AKMT2AMEN1ALDH1A1SCN5A
SCHEMBL710936 0.76 SCN9A (0.56) SCN9ASCN5ASCN1ASCN8A
SCHEMBL711919 0.74 SCN9A (0.67) SCN9AMAPTSMN1; SMN2SCN5ASCN1A
SCHEMBL714308 0.74 KMT2A (0.51) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL4967377 0.74 HSD11B1 (0.63) SCN9AKMT2AMEN1POLBKDM1A
SCHEMBL4966321 0.72 HSD11B1 (0.58) SCN9AKMT2AMEN1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN9A 17/4885KMT2A 1945/4885MEN1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.